Mologic

Mologic is a leading force in the development of rapid diagnostic products and technology. Having re-established its independence in 2014, the company has advanced a 10 product portfolio to pre-market evaluation, with 3 products receiving CE mark approval in 2016. The remaining products are destined for launch in 2017 and 2018, culminating in the completion of the worlds first respiratory disease exacerbation monitor. The company's interests lay beyond just human healthcare, with active programmes on large animal disease diagnostics and vaccine innovation exploiting the advances in technology from the human sector. Underpinning the new product development pathway, Mologic continues to deliver high value contract partnering projects for a range of national and international clients. It's broad range to skills and experience, including a low volume manufacturing facility (ISO13485 certified) enable the business to take on almost any project challenge, irrespective of size, complexity or stage. Mologic provides reagents, products and innovation, offering a fully harmonised service extending from idea through to initial product volumes. Through our professional partnerships, successful products can achieve high volume manufacturing, distribution and regulatory support across the globe.